During a public hearing Wednesday to discuss a newly proposed rare disease framework, FDA center director Michael Davis, M.D.

Biogen's CEO has pointed to the company's ability to take five drugs into clinical trials so far this year as evidence of its new focus on early-stage R&D. | Biogen's CEO has pointed to the company's ...

Chicago-based Syntax Bio believes it has cracked the code for turning stem cells into pancreatic beta cells in as little as ...

Every ESMO conference is eventful, but the drama kicked into gear earlier than expected this year when the eagerly ...

Corxel Pharmaceuticals may not have always planned to dust off the special purpose acquisition company (SPAC) route to the ...

Boehringer Ingelheim and Microsoft have launched a collaboration to explore the use of AI-powered digital patient twins to improve clinical trial design. | Boehringer Ingelheim and Microsoft have ...

“If Powerful AI is directed at solving humanity’s hardest problems and the risks are managed responsibly, the potential is ...

Lycia Therapeutics went public with an upsized $317.5 million IPO on Friday, while immunology-focused Windward Bio has also seen which way the public markets are blowing. | Lycia Therapeutics went ...

Incyte has pointed to a spread of phase 1 data for its KRAS G12D inhibitor as proof that the company has a worthy rival to Revolution Medicines in this newly hot cancer space. | Incyte has pointed to ...

BioNTech has reported modest efficacy and unexpected safety findings in a phase 3 breast cancer trial, leading the company to ...

Genmab may have arrived in Spain with updated data from a pair of phase 2 studies from the main prize of its Merus buyout, ...

Bristol Myers Squibb (BMS) has shared more details with Fierce about the death of a patient who received the pharma's investigational CAR-T in a multiple sclerosis (MS) trial. | Bristol Myers Squibb ...